Related Experiment Video

Updated: Mar 3, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Avelumab Impresses in Merkel Cell Carcinoma

    Cancer Discovery
    |April 26, 2017
    PubMed

    Insights

    Avelumab, a PD-L1 inhibitor, showed durable responses in Merkel cell carcinoma patients. This finding supported its FDA approval for treating this rare skin cancer.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Dermatology

    Background:

    • Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer.
    • PD-L1 expression can be a biomarker in certain cancers.
    • Avelumab targets the PD-L1 pathway to enhance anti-tumor immune response.

    Purpose of the Study:

    • To evaluate the efficacy and safety of avelumab in patients with metastatic Merkel cell carcinoma.
    • To assess the durability of responses to avelumab treatment.

    Main Methods:

    • An international, open-label, prospective Phase II clinical trial.
    • Patients received avelumab intravenously.
    • Response assessment was based on RECIST criteria.

    Main Results:

    • Avelumab demonstrated a high objective response rate.
    • A significant proportion of responders achieved durable responses.
    • The safety profile of avelumab was consistent with previous studies.

    Conclusions:

    • Avelumab is an effective treatment option for patients with Merkel cell carcinoma.
    • Durable responses observed support its role in managing this disease.

    More Related Videos

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

    Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

    Published on: April 22, 2019

    12.4K
    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

    Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

    Published on: October 27, 2014

    27.9K

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    2.1K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.0K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.8K